These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18067209)

  • 1. Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients.
    Zissimopoulos A; Matthaios D; Matthaiou E; Mantadakis E; Karaitianos I
    J BUON; 2007; 12(4):505-11. PubMed ID: 18067209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
    J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma.
    Gedik GK; Kiratli PO; Tascioglu B; Aras T
    Saudi Med J; 2006 Mar; 27(3):317-22. PubMed ID: 16532090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
    Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
    Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy.
    Nicolini A; Ferrari P; Sagripanti A; Carpi A
    Br J Cancer; 1999 Mar; 79(9-10):1443-7. PubMed ID: 10188888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between bone scintigraphy and tumor markers in patients with breast carcinoma.
    Begić A; Kucukalić-Selimović E; Obralić N; Durić O; Lacević N; Skopljak A
    Bosn J Basic Med Sci; 2006 Feb; 6(1):75-7. PubMed ID: 16533185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single determination of CA 15.3 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer.
    Crippa F; Bombardieri E; Seregni E; Castellani MR; Gasparini M; Maffioli L; Pizzichetta M; Buraggi GL
    J Nucl Biol Med (1991); 1992; 36(1):52-5. PubMed ID: 1450226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between bone scintigraphy and tumor markers in patients with breast cancer.
    Yildiz M; Oral B; Bozkurt M; Cobaner A
    Ann Nucl Med; 2004 Sep; 18(6):501-5. PubMed ID: 15515750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The status of nuclear medicine techniques in the diagnosis of bone metastases in breast cancer.
    Makaiová I; Kausitz J; Hupka S; Michaliková B; Vivodová M; Bohunický L
    Czech Med; 1989; 12(1):34-9. PubMed ID: 2498049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA.
    Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Winkel P; Mouridsen HT; Dombernowsky P
    Ann Oncol; 1993 Dec; 4(10):861-9. PubMed ID: 8117606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
    Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
    Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer.
    Montravers F; Younsi N; Rousseau C; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
    Anticancer Res; 1997; 17(3B):1683-6. PubMed ID: 9179218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Reliability of CA 15-3 in the follow up of female patients with breast carcinoma and bone metastases].
    del Rocío Estrada-Sánchez G; Mireles Enríquez M; Valverde Castañeda N
    Rev Invest Clin; 2003; 55(4):412-8. PubMed ID: 14635605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical significance of bone scintigraphy for early detection of bone metastasis from breast cancer].
    Wada T; Hohjoh T; Matunami N; Yamato M; Kadota K; Morikawa E; Hara S; Matsuda T; Yasutomi M
    Nihon Gan Chiryo Gakkai Shi; 1989 Apr; 24(4):781-5. PubMed ID: 2778373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis of bone and liver metastases in breast cancer comparing tumor markers and imaging techniques.
    Zanco P; Rota G; Sportiello V; Borsato N; Ferlin G
    Int J Biol Markers; 1989; 4(2):103-5. PubMed ID: 2768888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between CEA, TPA, CA 15/3 and hydroxyproline, alkaline phosphatase, whole body retention of 99mTc MDP in the follow-up of bone metastases in breast cancer.
    Francini G; Montagnani M; Petrioli R; Paffetti P; Marsili S; Leone V
    Int J Biol Markers; 1990; 5(2):65-72. PubMed ID: 2283479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis of skeletal metastases by serum tumor markers].
    Shinozaki T; Chigira M
    Nihon Seikeigeka Gakkai Zasshi; 1991 Aug; 65(8):441-6. PubMed ID: 1720162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical markers for assessment of bone metastases in patients with breast cancer.
    Hou MF; Tsai LY; Tsai SM; Huang CJ; Huang YS; Hsieh JS; Chan HM; Wang JY; Chuang CH; Chen FM; Huang TJ
    Kaohsiung J Med Sci; 1999 Aug; 15(8):452-60. PubMed ID: 10518361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism.
    Meijer WG; van der Veer E; Jager PL; van der Jagt EJ; Piers BA; Kema IP; de Vries EG; Willemse PH
    J Nucl Med; 2003 Feb; 44(2):184-91. PubMed ID: 12571207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.